Bata India Q4 profit plunges; Indoco jumps on EU GMP

What moved the stocks on May 29, 2026

Two results and regulatory updates set the tone for stock-specific action on May 29, 2026. Bata India shares fell about 3 percent after the footwear maker reported a sharp year-on-year decline in fourth-quarter earnings. In contrast, Indoco Remedies shares rose about 4 percent in early trade after the company received European Union Good Manufacturing Practice (EU GMP) certification from the German Health Authority (Berlin). The certification relates to Indoco’s Oral Solid Dosage (OSD) manufacturing facility at Baddi, Himachal Pradesh.

The moves underline how markets tend to react quickly to earnings surprises and compliance-related milestones. For consumer-facing companies, profit performance can dominate the narrative even when revenue grows. For pharmaceutical manufacturers, regulatory approvals and certifications often influence investor sentiment because they can support international market access.

Bata India: shares drop after steep profit decline

Bata India’s stock slipped around 3 percent after the company disclosed a sharp deterioration in profitability for the March quarter. Consolidated profit plunged 95.2 percent year-on-year to Rs 2.2 crore from Rs 45.9 crore in the corresponding quarter last year. The earnings compression came even as the company posted revenue growth.

Revenue rose 5 percent to Rs 827.6 crore in Q4, compared with Rs 788.2 crore a year earlier. The combination of higher revenue and sharply lower profit points to pressure on profitability during the quarter. The company’s update triggered an immediate negative reaction in the stock, reflecting investor focus on bottom-line strength.

What the Q4 numbers show

The headline numbers show a clear split between sales momentum and earnings delivery. A 5 percent rise in revenue indicates that demand and topline execution held up compared with the prior-year quarter. But the 95.2 percent drop in profit indicates the quarter was significantly weaker on earnings.

Investors typically track whether revenue growth translates into profit growth, particularly for established consumer brands. When that linkage breaks sharply in a single quarter, the market often reassesses near-term expectations. In Bata India’s case, the magnitude of the year-on-year profit drop was the most prominent data point in the disclosure.

Indoco Remedies: EU GMP certification drives early gains

Indoco Remedies shares gained about 4 percent in opening trade on May 29 after the company announced an EU GMP certification win. The company said the German Health Authority (Berlin) granted EU GMP certification for its Oral Solid Dosage (OSD) manufacturing facility (Plant III) at Baddi, Himachal Pradesh.

At 09:34 am, Indoco Remedies was quoting at Rs 212.10, up Rs 8.35, or 4.10 percent, on the BSE. The regulatory milestone was linked to an inspection conducted from April 22 to April 27, 2026. The company said the EU GMP certification confirms that the facility complies with Good Manufacturing Practice requirements as referred to in the EC Directive.

What EU GMP certification means for the Baddi facility

EU GMP certification is a quality and compliance validation that is widely tracked in the pharmaceutical industry. In its disclosure, Indoco Remedies linked the certification directly to Good Manufacturing Practice requirements referenced in the EC Directive. For manufacturers, such certifications are closely watched because they can support regulated-market business prospects.

Indoco’s announcement was specific to its formulations manufacturing set-up at Baddi. The company identified the certified unit as its OSD manufacturing facility (Plant III). The inspection window, April 22 to April 27, 2026, provides a clear timeline for when the assessment took place.

Management commentary and earlier EU certification

Indoco Remedies included a management comment alongside the update. “The EU GMP certification for our formulations manufacturing plant is a testament to our commitment to delivering high quality products to patients across the globe," said Aditi Panandikar, Managing Director – Indoco Remedies.

The company also pointed to a second, earlier compliance milestone at the same location. Earlier in the month, its solid oral dosage manufacturing facility (Unit I) at Baddi received EU GMP certification from the Malta Medicines Authority. Indoco said the Malta Medicines Authority inspected Unit I from January 29, 2026 to February 03, 2026.

Stock levels, prior close, and 52-week range

Indoco Remedies’ price action on May 29 followed an active prior session as well. In the previous trading session, the stock closed at Rs 203.75, higher by Rs 9.90 or 5.11 percent. On May 29, the early quote of Rs 212.10 reflected further gains at the time mentioned.

The stock’s 52-week high stood at Rs 348.10 on July 17, 2025, while the 52-week low was Rs 163.70 on March 30, 2026. At the reported levels, the stock was trading 41.47 percent below its 52-week high and 24.47 percent above its 52-week low. Indoco Remedies’ market capitalisation was reported at Rs 1,880.69 crore.

Key facts at a glance

Market impact: what investors are reacting to

For Bata India, the market reaction focused on profitability. The company reported revenue growth, but the scale of the profit decline dominated immediate sentiment, leading to the reported 3 percent fall in the stock. Such moves typically reflect how quickly the market re-prices near-term expectations when quarterly earnings surprise on the downside.

For Indoco Remedies, the reported rise aligned with a compliance and quality milestone. EU GMP certification is often treated as an operational and regulatory positive, especially when it is tied to a specific facility and inspection dates. The stock’s early rise to Rs 212.10 on the BSE also came after a strong previous session close, suggesting the announcement reinforced recent momentum.

Why this matters for consumer and pharma investors

The two updates highlight different drivers of stock performance across sectors. In consumer-facing businesses like footwear, quarterly profitability can be a decisive factor even if revenue is still growing. Investors typically look for consistency in earnings, and a large year-on-year drop can shift focus to margins and cost discipline.

In pharmaceuticals, regulatory certifications can be important signals of manufacturing readiness and compliance alignment with global standards. Indoco’s back-to-back EU GMP certifications for facilities at Baddi, one from the Malta Medicines Authority and another from the German Health Authority (Berlin), kept attention on its manufacturing footprint in Himachal Pradesh.

Closing take

Bata India’s reported Q4 profit decline and Indoco Remedies’ EU GMP certification resulted in opposite stock reactions on May 29, 2026. Bata’s shares fell about 3 percent after profit dropped to Rs 2.2 crore despite revenue rising to Rs 827.6 crore. Indoco’s shares rose about 4 percent after it received EU GMP certification for its Baddi OSD Plant III following an April 22-27, 2026 inspection, with the stock quoted at Rs 212.10 on the BSE at 09:34 am.

The next market cues for both names will depend on subsequent company updates and disclosures, including any follow-through information linked to business performance or operational milestones.